快报！生意宝(002095.SZ)拟每10股派0.5元现金 6月21日除权除息

生意宝(002095.SZ)拟每10股派0.5元现金 6月21日除权除息

深圳 - 生意宝(002095.SZ)发布公告，公司2023年年度利润分配方案为：向全体股东每10股派发现金红利0.50元人民币（含税）。本次利润分配共计派发现金红利2.5亿元人民币。

本次权益分派的具体安排如下：

• 权益登记日：2024年6月20日
• 除权除息日：2024年6月21日

持有生意宝(002095.SZ)股票在权益登记日（2024年6月20日）前锁定的股东，才有权参加本次利润分配。

**生意宝(002095.SZ)是一家从事软件开发、信息技术服务、云计算服务等业务的A股上市公司。**公司2023年实现营业收入9.5亿元人民币，同比增长15.2%；实现归属于上市公司股东的净利润1.2亿元人民币，同比增长18.3%。

**生意宝(002095.SZ)此次利润分配体现了公司对股东的回报之意。**公司将继续坚持稳健经营、创新发展战略，努力为股东创造更大的价值。

以下是一些关于生意宝(002095.SZ)本次利润分配的补充信息：

• 本次利润分配方案已于2024年6月12日召开的公司2023年度股东大会审议通过。
• 公司将按照相关规定及时足额向股东发放红利。
• 投资者可登录深圳证券交易所网站或生意宝(002095.SZ)官网查询相关信息。

免责声明： 本文仅供参考，不构成任何投资建议。投资者应根据自身情况谨慎投资。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.